Effectiveness of Dymista® in patients with allergic rhinitis and asthma

Study summary

No information provided.

Study identification

• EU PAS number:
  EUPAS30940
• Study ID:
  30941
• Official title and acronym:
  Effectiveness of Dymista® in patients with allergic rhinitis and asthma
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  A pre-post historical cohort study evaluating the effectiveness of a novel combination therapy of antihistamine and intranasal corticosteroid (Dymista®) on asthma-related outcomes among patients with allergic rhinitis and asthma multi-morbidity. The primary objective is to examine the effectiveness of Dymista® in terms of improving asthma control by comparing the number of acute respiratory events and other measures of asthma control in the year before and after initiation of Dymista®.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Observational & Pragmatic Research Institute Pte (OPRI)

United Kingdom

Study timelines

Date when funding contract was signed

Planned:03/05/2019

Actual:25/02/2019

Study start date

Planned:24/05/2019

Actual:24/04/2019

Data analysis start date

Planned:24/05/2019

Actual:24/04/2019

Date of final study report

Planned:23/08/2019

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Mylan

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable